Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO‐E.W.I.N.G. 99 clinical trial
Pediatric Blood & Cancer2006Vol. 47(1), pp. 22–29
Citations Over TimeTop 10% of 2006 papers
Christine Juergens, Claire Weston, Ian Lewis, Jeremy Whelan, Michael Paulussen, Odile Oberlin, Jean Michon, A. Zoubek, H. Juergens, Alan Craft
Abstract
AR under VIDE remained within the expected range. Some AR, for example, hematotoxicity were significantly influenced by age and gender but not by tumor volume. G-CSF did not significantly influence neutropenia-related fever and infection. Solicited safety collection with checklists adequately reflects the burden per course.
Related Papers
- → Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood: A pediatric oncology group study(1993)6 cited
- → A Phase I/II Study of a 72‐h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma(1997)5 cited
- → Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors(1982)28 cited
- [Phase II study with etoposide/vincristine in small cell bronchial cancer (extensive disease)].(1990)